Nasim Bahar
About Nasim Bahar
Nasim Bahar is the HEOR Director Europe at BeiGene in Basel, Switzerland, with extensive experience in the pharmaceutical and biotech industries, including roles at AstraZeneca, Takeda, Bayer, Roche, and Novartis.
Title
Nasim Bahar currently holds the position of HEOR Director Europe at BeiGene, based in Basel, Switzerland.
Professional Experience in Pharmaceutical/Biotech Industry
Nasim Bahar has extensive experience in the pharmaceutical and biotech sectors, having previously worked at Astra Zeneca, Takeda, and Bayer as Global HEOR Leader/Director from 2018 to 2020 in Basel, Switzerland. Earlier, he served as the Global HTA Access Evidence Submission Lead and Value and Synthesis Lead at Roche between 2015 and 2018, also in Basel. From 2009 to 2015, he was a Senior Clinical Manager for Oncology and Infectious Diseases at Novartis, based in Basel.
Early Career and Humanitarian Work
Nasim Bahar's earlier career includes significant roles in public policy and international development. He worked as an International Public Policy Manager at Roche from 2008 to 2009 in Switzerland. He was also a Public Health & Policy Consultant at Breakthrough Breast Cancer, NICE & NHS Consultancy in the UK from 2002 to 2005. His humanitarian involvement includes being an External Consultant at the European Commission Humanitarian Office from 1995 to 1997 in Brussels, Belgium.
Education and Expertise
Nasim Bahar earned an MSc in Public Health and Policy from the London School of Hygiene and Tropical Medicine, focusing on communicable and infectious diseases, and sexual health. He also holds an MSc (Econ) in Development, Population and Economic Geography from The London School of Economics and Political Science (LSE). His academic background is complemented by a BA (Honours) in Economics.
Specialist Expertise and Advocacy
Nasim Bahar has a deep understanding of oncology, particularly in solid tumors and rare cancers like sarcomas. He is passionate about evidence-based oncology patient advocacy, especially within NICE and UK NGOs. He has been involved in European governmental policy activities and has worked on global drug studies for infectious diseases, including Hepatitis C.